← All trials
NCT01548924
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2012
- Primary completion
- Feb 1, 2013
- Completion date
- Aug 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Universidad Carlos III MadridLead sponsor
- Universidad Carlos III MadridOverall official - principal investigator
- Universidad Carlos III MadridStudy director
- University of Texas at HoustonCollaborator
- Hospital Universitario de FuenlabradaCollaborator
- University of BarcelonaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.